Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis

European Journal of Clinical Investigation

Volumn 42, Issue 7, 2012, Pages 693-701

  Winkler, Karl ^a   Hoffmann, Michael M ^a   Krane, Vera ^b   Drechsler, Christiane ^b   Wanner, Christoph ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Coronary artery disease (CAD); Haemodialysis; Lipoprotein associated phospholipase A2 (LpPLA2); Statin treatment; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; LIPOPROTEIN; PHOSPHOLIPASE A2; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYING; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AREA UNDER CURVE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRROLES; RENAL DIALYSIS; RISK FACTORS;

EID: 84862620611     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02634.x     Document Type: Article

References (17)

1. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
2. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010;268:348-58.
3. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93.
4. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schafer G, Seelhorst U et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2007;53:1440-7.
5. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers PAF-AH activity: a placebo controlled trial in patients with type 2 diabetes. J Cin Endocrinol Metab 2004;89:1153-9.
6. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 2005;353:238-48.
7. Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011;6:1316-25.
8. Wanner C, Krane V, Marz W. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259-66.
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
10. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosanto M et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 2000;296:151-61.
11. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Eng J Med 2009;360:1395-407.
12. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33.
13. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
14. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-21.
15. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-7.
16. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004;109:837-42.
17. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.